Successful transfemoral core valve aortic valve implantation in a patient with degenerated solofreedom biologic supravalvular aortic valve

Matjaž Bunc¹,4, Polonca Kogoj¹, Jana Ambrožič⁵, Špela Mušič², Nikola Lakič², Borut Geršak²

¹Department of Cardiology, University Medical Centre Ljubljana, Zaloška c. 007, 1000 Ljubljana, ²Department for Cardio and Vascular Surgery, University Medical Centre Ljubljana, ³Department of Radiology, University Medical Centre Ljubljana, Zaloška c. 007, 1000 Ljubljana, ⁴Department of Pathophysiology, School of Medicine, Zaloška c.002, 1000 Ljubljana

Abstract

Percutaneous aortic valve implantation (TAVI) is well established treatment option for high risk patients with severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) is an attractive treatment option for patients with failing bioprostheses (valve-in-valve concept), especially in elderly patients with high risk for reoperation. Although clinical experience is still limited for this off-label indication, the procedure has been shown to be feasible in stented as well as stentless bioprostheses. We report a case of of 71-years old woman were CoreValve 23 mm (Medtronic, Inc., Minneapolis, Minnesota, USA) was implanted inside a degenerated Sorin Freedom SOLO bioprosthesis using transfemoral approach. Freedom SOLO bioprosthesis stentless bioprosthesis is sutured in supra-annular position and presents a TAVI challenge due to its proximity to coronary ostia. Careful pre-procedural planning with TEE and CTA is crucial. We decided for transfemoral approach with 23 mm CoreValve implantation. Balloon valvuloplasty before TAVI with contrast injection may predict the final result and is helpful for procedure success and risk reduction. The final TAVR result was good. This case proves the ViV concept for stentless Freedom SOLO bioprosthesis.

Key words TAVI, SOLO Freedom, stentless bioprosthesis, degeneration, valve in valve

Background

The most effective treatment for patients with severe symptomatic aortic stenosis is surgical replacement of the valve. Aortic valve replacement with a bioprosthesis is preferred, especially in older populations, due to its satisfactory hemodynamic performance without warfarin related complications. Sorin Freedom SOLO bioprosthesis (Sorin Biomedica Cardio, Saluggia, Italy) is implanted in the supra-annular position. According to available data the SOLO valve is durable with good hemodynamic performance and low complication rates. In our institution more than 500 implantations were performed in the last 8 years. It should not be unexpected that a considerable number of patients may require reintervention due to a dysfunctional bioprosthesis with structural valve deterioration. Surgical treatment of degenerated aortic bioprostheses is associated with an increased risk of morbidity and mortality, especially in elderly patients with significant co-morbidities. Therefore, transcatheter aortic valve implantation (TAVI) performed as valve in valve (ViV) technique appears as an attractive alternative treatment option. Pericardial stentless aortic bioprosthesis Freedom Solo represents a challenge for ViV implantation due to its supra-annular position potentially leading to coronary obstruction.

We report a case of ViV implantation by transfemoral approach with a 23-mm self-expandable prosthesis Core-Valve (Medtronic, Inc., Minneapolis, Minnesota, USA) inside a degenerated Sorin Freedom SOLO bioprosthesis.

Case presentation

(Core Valve in Freedom Solo valve)

71-years old woman underwent surgical aortic valve replacement with a 25-mm Freedom Solo bioprosthesis in 2007. During the same surgical procedure bypass graft with left internal mammary artery (LIMA) left to LAD and venous grafts to the first (OM1) and second (OM2) obtuse marginal coronary artery was also done. Five years after the surgery she presented to our institution with dyspnea (New York Heart Association functional class II to III). Echocardiographic examination revealed degeneration of the aortic bioprosthesis (mean gradient across the aortic valve of 28 mmHg and aortic valve area of 0.83 cm²). She refused any other further evaluation and tre-
atment and was discharged. She presented again after one year with severe heart failure. An echocardiogram revealed a progression of the biologic aortic valve degeneration with severe aortic stenosis (mean gradient of 50 mmHg, aortic valve area of 0.6 cm$^2$) and mild to moderate aortic regurgitation. The global systolic function of the left ventricle was preserved with the ejection fraction of 65%. A severe pulmonary hypertension of 85 mmHg was also found. Cardiac catheterization showed patent coronary artery bypasses with no new significant disease on other coronary arteries. Due to several comorbidities (chronic obstructive pulmonary disease with severe obstructive and restrictive respiratory failure, chronic renal disease, diabetes on insulin, severe obesity, previous cardiac surgery) the surgical risk was high (logistic Euroscore of 31%) and she was refused for aortic valve re-replacement. TAVI was considered and shown to be feasible after morphological evaluation with multidetector computed tomography and transesophageal echocardiography.

One week after the admission we performed the percutaneous procedure under general anesthesia. First we inserted a SPIDER Embolic Protection Device in the right internal carotid artery to prevent embolic events. Then balloon aortic valvuloplasty with aortic angiography was done for the final valvular sizing and to explore the anatomical relation of the opened surgical prosthesis leaflets to the coronary ostia (Figure 1 B). After the valvoplasty a 23-mm self-expandable CoreValve (Medtronic, Inc., Minneapolis, Minnesota, USA) was implanted via femoral access (Figure 1 C). The transcatheter prosthesis was expanded during rapid pacing under fluoroscopic and transesophageal guidance. The final angiographic result was excellent, showing good opening of the transcatheter valve leaflets and fully patent coronary ostia (Figure 1 D). Echocardiogram after implantation showed good hemodynamic properties of the transcatheter valve with a maximal gradient of 20 mmHg, estimated aortic valve area of 1.7 cm$^2$ and mild paravalvular regurgitation (Figure 2).

Discussion

Increased life expectancy and improvement in clinical outcome following surgery has led to an increasing number of elderly patients with a history of prior aortic valve replacement (AVR). As a consequence, a considerable number of patients may require reintervention due to a dysfunctional bioprosthesis with structural valve deterioration. Transcatheter aortic valve implantation (TAVI) has become an established surgical alternative in patients...
with aortic stenosis and severe comorbidities. Freedom Solo aortic valve is stentless bioprosthesis that is implanted in a supra-valvular position, which is particularly beneficial in elderly patients with severely calcified aortic valves rendering difficult the conventional implantation in the annular position.2,3,5

During valve-in-valve implantation supra-annular bioprosthesis position presents a technical challenge since bioprosthetic leaflets may extend to aortic wall and potentially obstruct coronary ostia. Careful pre-procedural planning with multidetector computed tomography and three-dimensional transesophageal echocardiography is important for the assessment of aortic root anatomy, relationship of the bioprosthetic leaflet height in relation to coronary ostia and size of the prosthesis orifice.10,11 In addition, balloon valvuloplasty before TAVI is useful for checking the position of the opened bioprosthetic leaflets in relation to coronary ostia and for final valvular sizing.

In the reported case we have shown that valve-in-valve procedure for failing supra-annular bioprosthesis Freedom Solo is feasible, considering technical difficulties.

References